



Press release

## **Memory Pharmaceuticals Corp. is listed on the NASDAQ**

**Zug/Munich/London**, 7 April 2004 – *Global Life Science Ventures (GLSV)* today announced that a fourth portfolio company financed through its first fund, Memory Pharmaceuticals Corp., went public earlier this week through a listing on the NASDAQ. On Monday April 5, shares of the Montvale, New Jersey-based company began trading on the NASDAQ National Market under the symbol “MEMY”. UBS Investment Bank acted as underwriter for the offering; SG Cowen Securities Corporation, Banc of America Securities LLC and Fortis Securities LLC were co-managers.

Memory Pharmaceuticals Corp. is a neuropharmaceutical drug development company active in the field of learning and memory disorders. The company discovers and develops innovative drug candidates for the treatment of central nervous system (CNS) conditions that show significant impairment of memory and other cognitive functions. These conditions include neurological diseases associated with aging, such as Alzheimer’s disease, vascular dementia and mild cognitive impairment, and also include certain psychiatric disorders such as depression and schizophrenia.

Dr. Peter Reinisch, Partner at GLSV, remarked: “The public listing on the NASDAQ of Memory Pharmaceuticals is a major milestone for the company and its investors. Memory has made rapid progress in advancing its lead drug candidates from initial identification up to phase II clinical trials. The public listing will ensure that Memory has the resources to build on its impressive track record to date.”

Through its first fund, GLSV has supported Memory Pharmaceuticals through three consecutive rounds of financing in 1998, 2000 and 2002.

### **About Global Life Science Ventures:**

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany, Switzerland, and the UK, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than €200 million. Up to now, GLSV has financed 29 leading biotechnology companies, five of which have completed a successful exit through IPO or trade-sale. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.



**Global Life Science Ventures – one team – three locations – global perspective**

**Germany**

GLSV GmbH  
Von-der-Tann-Str. 3  
D – 80539 München  
Tel. +49 (0)89 288 151 0  
Fax +49 (0)89 288 151 30  
[www.glsv-vc.com](http://www.glsv-vc.com)  
[mailbox@glsv-vc.com](mailto:mailbox@glsv-vc.com)

**Switzerland**

GLSV AG  
Postplatz 1, P.O. 626  
CH – 6301 Zug  
Tel. +41 (0)41 727 19 40  
Fax +41 (0)41 727 19 45

**UK**

GLSV Ltd.  
1, Northumberland Avenue  
London WC2N 5BW, UK  
Tel. +44 (0)20 89 38 66 92  
Fax +44 (0)20 89 38 77 40

For additional information, please contact:

**Rochat & Partners**

Christophe Lamps  
Tel. +41 22 718 37 46  
Fax +41 22 786 54 58  
E-mail: [clamps@rochat-pr.ch](mailto:clamps@rochat-pr.ch)